Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed/refractory hairy cell leukemia.Robert J. Kreitman, Ira Pastan, Constance M. Yuan et al.|Journal of Clinical Oncology|2021Cited by 0